Changes in overactive bladder symptoms after withdrawl of solifenacin following initial 12-week combination therapy with tamsulosin: A multicenter prospective study in men with benign prostatic hyperplasia and coexisting overactive bladder

Trial Profile

Changes in overactive bladder symptoms after withdrawl of solifenacin following initial 12-week combination therapy with tamsulosin: A multicenter prospective study in men with benign prostatic hyperplasia and coexisting overactive bladder

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Solifenacin (Primary) ; Tamsulosin
  • Indications Benign prostatic hyperplasia; Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 19 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top